share_log

HOOKIPA Pharma | PRE 14A: Preliminary proxy statements relating to merger or acquisition

HOOKIPA Pharma | PRE 14A: Preliminary proxy statements relating to merger or acquisition

HOOKIPA Pharma | PRE 14A：并购重组委托声明
美股sec公告 ·  04/16 16:01
Moomoo AI 已提取核心信息
HOOKIPA Pharma Inc. (HOOKIPA) has announced a series of corporate actions involving its stock, including a reverse stock split, an increase in authorized shares, and a potential stock purchase by Gilead Sciences, Inc. The company's Board of Directors has approved an amendment to increase authorized common stock from 200 million to 400 million shares, subject to stockholder approval. Concurrently, stockholders are being asked to authorize a reverse stock split at a ratio between 1-for-2 and 1-for-10, to be determined by the Board, with the aim of increasing the per-share trading price and maintaining NASDAQ listing requirements. Additionally, HOOKIPA entered into an amended stock purchase agreement with Gilead Sciences, allowing Gilead to purchase up to $35 million of HOOKIPA's common stock. The company's 2024 Annual Meeting of Stockholders is set to address these proposals, with the Board recommending stockholder approval for both the increase in authorized shares and the reverse stock split.
HOOKIPA Pharma Inc. (HOOKIPA) has announced a series of corporate actions involving its stock, including a reverse stock split, an increase in authorized shares, and a potential stock purchase by Gilead Sciences, Inc. The company's Board of Directors has approved an amendment to increase authorized common stock from 200 million to 400 million shares, subject to stockholder approval. Concurrently, stockholders are being asked to authorize a reverse stock split at a ratio between 1-for-2 and 1-for-10, to be determined by the Board, with the aim of increasing the per-share trading price and maintaining NASDAQ listing requirements. Additionally, HOOKIPA entered into an amended stock purchase agreement with Gilead Sciences, allowing Gilead to purchase up to $35 million of HOOKIPA's common stock. The company's 2024 Annual Meeting of Stockholders is set to address these proposals, with the Board recommending stockholder approval for both the increase in authorized shares and the reverse stock split.
HOOKIPA Pharma Inc.（HOOKIPA）宣布了一系列涉及其股票的公司行动，包括反向股票拆分、增加授权股份以及吉利德科学公司可能购买股票。公司董事会已批准一项修正案，将授权普通股从2亿股增加到4亿股，但须经股东批准。同时，要求股东批准反向股票拆分，比例在1比2和1比10之间，由董事会决定，目的是提高每股交易价格并维持纳斯达克的上市要求。此外，HOOKIPA与吉利德科学签订了经修订的股票购买协议，允许吉利德购买高达3500万美元的HOOKIPA普通股。该公司的2024年年度股东大会将讨论这些提案，董事会建议股东批准增加授权股票和反向股票拆分。
HOOKIPA Pharma Inc.（HOOKIPA）宣布了一系列涉及其股票的公司行动，包括反向股票拆分、增加授权股份以及吉利德科学公司可能购买股票。公司董事会已批准一项修正案，将授权普通股从2亿股增加到4亿股，但须经股东批准。同时，要求股东批准反向股票拆分，比例在1比2和1比10之间，由董事会决定，目的是提高每股交易价格并维持纳斯达克的上市要求。此外，HOOKIPA与吉利德科学签订了经修订的股票购买协议，允许吉利德购买高达3500万美元的HOOKIPA普通股。该公司的2024年年度股东大会将讨论这些提案，董事会建议股东批准增加授权股票和反向股票拆分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息